Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 21, Issue 2, 2002, Pages 155-164

  Reddy, Bandaru S ^a   Rao, Chinthalapally V ^a  

^a AMERICAN HEALTH FOUNDATION   (United States)

Author keywords

Celecoxib; Chemoprevention; Colon cancer; Curcumin; Cyclooxygenase 2inhibitors; Nonsteroidal anti inflammatory drugs; Phytosterols; Piroxicam; Rofecoxib; Sulindac

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ACETYLSALICYLIC ACID; CELECOXIB; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; KETOPROFEN; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHYTOSTEROL; PIROXICAM; ROFECOXIB; SULINDAC;

ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON CANCER; COLON CARCINOGENESIS; COLON POLYPOSIS; COLORECTAL CANCER; CONFERENCE PAPER; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL;

EID: 0036081685     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/jenvironpatholtoxicoloncol.v21.i2.90     Document Type: Conference Paper

References (48)

1. Cancer statistics, 2001
2. Chemoprevention of cancer
3. Perspectives on cancer chemoprevention research and drug development
4. Aspirin and the potential role of prostaglandins in colon cancer
5. Eicosanoids and the gastrointestinal tract
6. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
7. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors
8. Cyclooxygenase-2 inhibitors in tumorigenesis (Part I)
9. The relationship between cyclooxygenase-2 expression and colorectal cancer
10. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas
11. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2
12. Aspirin use and reduced risk of fatal colon cancer
13. A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large bowel cancer
14. Colorectal cancer risk, chronic illness, operations and medications: Case-control results form the Melbourne Colorectal Cancer Study
15. Sulindac for polyposis of the colon
16. Inhibition of initiation and promotion on N-methyl-nitrosourea-induced colon carcinogenesis in rats by non-steroidal anti-inflammatory agent indomethacin
17. Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea
18. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats
19. Non-steroidal antiinflammatory drugs
20. Sulindac causes regression of rectal polyps in familial adenomatous polyposis
21. Treatment of colonic rectal adenomas with sulindac in familial adenomatous polyposis
22. Aspirin use and the risk for colorectal cancer and adenomas in male health professionals
23. Prospects for preventing colorectal cancer
24. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development
25. Chemoprevention of colon carcinogenesis by sulindac, a non-steroidal antiinflammatory agent
26. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds
27. min mouse model by the nonsteroidal anti-inflammatory drug piroxicam
28. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
29. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II)
30. 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
31. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon cancer
32. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
33. Chemoprevention of colon cancer by specific cyclo-osygenase-2 inhibitor, celecoxib administered during different stages of carcinogenesis
34. min mouse
35. 716 mouse by rofecoxib, specific cyclooxygenase-2 inhibitor
36. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci in the rat colon
37. Chemo-prevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound
38. Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz-[a]anthracine-induced mammary cancer in rats
39. Chemopreventive effect of curcumin, a naturally-occurring antiinflammatory agent, during the promotion/progression stages of colon cancer
40. Lipoxygenase regulation of membrane expression of tumor cell glycoproteins and subsequent metastasis
41. Curcumin inhibits IL-1 and TNF-induction of AP-1 and NF-B DNA-binding activity in bone marrow stromal cells
42. Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adeno-carcinoma cell lines by a prostaglandin-independent pathway
43. Modulation of inducible nitric oxide synthase and cyclooxygenase activity of curcumin during different stages of experimental colon carcinogenesis
44. Polyamine metabolism and its importance in neoplastic growth and as a target as a chemotherapy
45. Early induction of rat colonic epithelial ornithine and S-adenosyl-L-methionine decarboxylase activities by N-methyl-N-nitro-N′-nitrosoguanidine or bile salts
46. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug, with D,L-difluoro-methylornithine, an ornithine decarboxylase inhibitor in diet
47. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potential chemopreventive effects of sulindac